Article
A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
Cancer letters - 1 Jan 2021
Grillo Elisabetta, Corsini Michela, Ravelli Cosetta, di Somma Margherita, Zammataro Luca, Monti Eugenio, Presta Marco, Mitola Stefania
Abstract excerpt
In cancer genomics, recurrence of mutations in gene families that share homologous domains has recently emerged as a reliable indicator of functional impact and can be exploited to reveal the pro-oncogenic effect of previously uncharacterized variants. Pan-cancer analyses of mutation hotspots in the catalytic domain of a subset of tyrosine kinase receptors revealed that two infrequent mutations of VEGFR2 (R1051Q...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.